Vaping among ex-smokers in England surged from 2% in 2013 to over 20% in 2024, driven by younger demographics and disposable e-cigarettes, raising questions about health implications and smoking relapse.
Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center | Psychedelic Invest
UK sites to participate in part of pivotal phase 3 program following Medicines and Healthcare Regulatory Agency approval of study Research will take place in